- Home
- AMS vs PSTV Comparison
AMS vs PSTV Comparison
Compare AMS & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- PSTV
- Stock Information
- Founded
- AMS 1980
- PSTV 1996
- Country
- AMS United States
- PSTV United States
- Employees
- AMS N/A
- PSTV N/A
- Industry
- AMS Medical Specialities
- PSTV Medical/Dental Instruments
- Sector
- AMS Health Care
- PSTV Health Care
- Exchange
- AMS Nasdaq
- PSTV Nasdaq
- Market Cap
- AMS 17.2M
- PSTV 17.0M
- IPO Year
- AMS N/A
- PSTV N/A
- Fundamental
- Price
- AMS $2.51
- PSTV $0.45
- Analyst Decision
- AMS
- PSTV Strong Buy
- Analyst Count
- AMS 0
- PSTV 4
- Target Price
- AMS N/A
- PSTV $7.88
- AVG Volume (30 Days)
- AMS 4.0K
- PSTV 8.4M
- Earning Date
- AMS 08-13-2025
- PSTV 08-14-2025
- Dividend Yield
- AMS N/A
- PSTV N/A
- EPS Growth
- AMS N/A
- PSTV N/A
- EPS
- AMS N/A
- PSTV N/A
- Revenue
- AMS $29,251,000.00
- PSTV $5,317,000.00
- Revenue This Year
- AMS $5.06
- PSTV $2.95
- Revenue Next Year
- AMS N/A
- PSTV $7.89
- P/E Ratio
- AMS N/A
- PSTV N/A
- Revenue Growth
- AMS 26.61
- PSTV N/A
- 52 Week Low
- AMS $2.27
- PSTV $0.16
- 52 Week High
- AMS $3.59
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- AMS 51.57
- PSTV 43.79
- Support Level
- AMS $2.45
- PSTV $0.39
- Resistance Level
- AMS $2.53
- PSTV $0.54
- Average True Range (ATR)
- AMS 0.07
- PSTV 0.05
- MACD
- AMS 0.00
- PSTV -0.02
- Stochastic Oscillator
- AMS 36.67
- PSTV 22.96
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).